These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

626 related items for PubMed ID: 19958778

  • 1. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
    Ferrario CM.
    Life Sci; 2010 Feb 27; 86(9-10):289-99. PubMed ID: 19958778
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Aliskiren and valsartan combination therapy for the management of hypertension.
    Epstein BJ.
    Vasc Health Risk Manag; 2010 Sep 07; 6():711-22. PubMed ID: 20859542
    [Abstract] [Full Text] [Related]

  • 4. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
    Bomback AS, Toto R.
    Am J Hypertens; 2009 Oct 07; 22(10):1032-40. PubMed ID: 19661925
    [Abstract] [Full Text] [Related]

  • 5. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.
    Cagnoni F, Njwe CA, Zaninelli A, Ricci AR, Daffra D, D'Ospina A, Preti P, Destro M.
    Vasc Health Risk Manag; 2010 Aug 09; 6():549-59. PubMed ID: 20730071
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K, Filipiak KJ, Gwizdala A, Tykarski A.
    Expert Rev Cardiovasc Ther; 2008 Jun 09; 6(5):759-71. PubMed ID: 18510491
    [Abstract] [Full Text] [Related]

  • 9. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
    Chrysant SG.
    Drugs Today (Barc); 2010 Mar 09; 46(3):151-62. PubMed ID: 20467589
    [Abstract] [Full Text] [Related]

  • 10. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?
    Bavishi C, Bangalore S, Messerli FH.
    Prog Cardiovasc Dis; 2016 Mar 09; 59(3):253-261. PubMed ID: 27777044
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS.
    J Assoc Physicians India; 2010 Feb 09; 58():102-8. PubMed ID: 20653151
    [Abstract] [Full Text] [Related]

  • 12. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 09; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 13. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C, Pöss J, Böhm M.
    Drugs; 2010 Jul 09; 70(10):1215-30. PubMed ID: 20568830
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study.
    Farcas A, Leucuta D, Bucsa C, Mogosan C, Dumitrascu D.
    Int J Clin Pharm; 2016 Dec 09; 38(6):1390-1397. PubMed ID: 27677980
    [Abstract] [Full Text] [Related]

  • 16. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr 09; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

  • 17. The role of direct renin inhibition in clinical practice: focus on combination therapy.
    Rashid HU, Mende C.
    Am J Cardiovasc Drugs; 2011 Oct 01; 11(5):303-15. PubMed ID: 21846157
    [Abstract] [Full Text] [Related]

  • 18. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J, Aparicio LS, Waisman GD.
    Rev Recent Clin Trials; 2011 May 01; 6(2):134-46. PubMed ID: 21241234
    [Abstract] [Full Text] [Related]

  • 19. The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
    Strauss MH, Hall AS.
    Prog Cardiovasc Dis; 2016 May 01; 58(5):473-82. PubMed ID: 26586276
    [Abstract] [Full Text] [Related]

  • 20. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
    Abassi Z, Winaver J, Feuerstein GZ.
    Biochem Pharmacol; 2009 Oct 15; 78(8):933-40. PubMed ID: 19477166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.